- Home
- ARCT vs CMRX Comparison
ARCT vs CMRX Comparison
Compare ARCT & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- CMRX
- Stock Information
- Founded
- ARCT 2013
- CMRX 2000
- Country
- ARCT United States
- CMRX United States
- Employees
- ARCT N/A
- CMRX 81
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- CMRX Health Care
- Exchange
- ARCT Nasdaq
- CMRX Nasdaq
- Market Cap
- ARCT 444.5M
- CMRX 797.3M
- IPO Year
- ARCT N/A
- CMRX 2013
- Fundamental
- Price
- ARCT $9.43
- CMRX $8.50
- Analyst Decision
- ARCT Strong Buy
- CMRX Hold
- Analyst Count
- ARCT 7
- CMRX 4
- Target Price
- ARCT $57.80
- CMRX $8.51
- AVG Volume (30 Days)
- ARCT 394.6K
- CMRX 8.4M
- Earning Date
- ARCT 03-06-2025
- CMRX 03-21-2025
- Dividend Yield
- ARCT N/A
- CMRX N/A
- EPS Growth
- ARCT N/A
- CMRX N/A
- EPS
- ARCT N/A
- CMRX N/A
- Revenue
- ARCT $152,310,000.00
- CMRX $212,000.00
- Revenue This Year
- ARCT N/A
- CMRX $2,685.38
- Revenue Next Year
- ARCT $39.21
- CMRX $1,050.23
- P/E Ratio
- ARCT N/A
- CMRX N/A
- Revenue Growth
- ARCT N/A
- CMRX N/A
- 52 Week Low
- ARCT $9.41
- CMRX $0.75
- 52 Week High
- ARCT $45.00
- CMRX $8.53
- Technical
- Relative Strength Index (RSI)
- ARCT 22.40
- CMRX 83.05
- Support Level
- ARCT $11.71
- CMRX $8.41
- Resistance Level
- ARCT $13.41
- CMRX $8.52
- Average True Range (ATR)
- ARCT 0.86
- CMRX 0.02
- MACD
- ARCT -0.30
- CMRX -0.15
- Stochastic Oscillator
- ARCT 0.39
- CMRX 62.50
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.